FDA's Combination Products Policy Council is reviewing recently submitted written comments from stakeholders recommending priorities for the group, but it currently has no specific timeframe by which it will address the feedback according to one of its top officials.
John "Barr" Weiner, an associate director at FDA's Office of Combination Products and a top official on the CPPC, says the council is reviewing comments submitted from five industry organizations and companies on combination product issues and may hold a public meeting if the subject matter warrants it